Company & Sponsor Intelligence
Eli Lilly and Company
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials34
Recruiting5
Completed24
Countries8
Therapeutic footprint
adhdalzheimersdepressionmigraine_headacheneuro_oncologypain_neuropathyschizophrenia
Indexed studies
NCT04396574A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
migraine_headache · United StatesPHASE3
migraine_headache · United StatesPHASE3
NCT01127633Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT00036309Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT01127646A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
adhd · NetherlandsPHASE4
adhd · NetherlandsPHASE4
NCT07641517A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
pain_neuropathy · United StatesPHASE2
pain_neuropathy · United StatesPHASE2
NCT00071708Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
depression · AustraliaAPPROVED_FOR_MARKETING
depression · AustraliaAPPROVED_FOR_MARKETING
NCT06568042Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
pain_neuropathy · United StatesPHASE2
pain_neuropathy · United StatesPHASE2
NCT00447278A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
adhd · BelgiumPHASE3
adhd · BelgiumPHASE3
NCT01445119A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
neuro_oncology · United StatesPHASE1
neuro_oncology · United StatesPHASE1
NCT00485875Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
adhd · United StatesPHASE4
adhd · United StatesPHASE4
NCT00485628Safety Study in Outpatient Japanese Children With ADHD
adhd · JapanPHASE2
adhd · JapanPHASE2
NCT00844857A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
depression · United StatesPHASE4
depression · United StatesPHASE4
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →